The Medicines Company (NASDAQ:MDCO) has scheduled a webcast and
conference call of its upcoming Infectious Disease Care Investor &
Analyst Day on Wednesday, September 24, 2014, from 9:00 am to 12:00 pm
Squibb Company (NYSE:BMY) today announced that the European
Medicines Agency (EMA) has validated for review the Marketing
Authorization Application (MAA) for nivolumab in non-small cell lung
cancer (NSCLC) – the first completed regulatory submission for a PD-1
immune checkpoint inhibitor in this tumor type.
Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today reviewed recent
progress and announced upcoming milestones in its efforts to develop
multiple combinations of medicines that treat the underlying cause of
cystic fibrosis (CF) for the majority of people with the disease.
Sign-up for Vertex Reviews Recent Progress and Announces Upcoming Milestones in the Development of Multiple Combinations of Medicines that Target the Underlying Cause of Cystic Fibrosis investment picks
The Medicines Company (NASDAQ:MDCO) has scheduled its quarterly
conference call for Wednesday, October 22 at 8:30 a.m. Eastern Time to
discuss third quarter financial results, guidance and operational
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the
Pharmacovigilance Risk Assessment Committee (PRAC) of the European
Medicines Agency (EMA) has concluded its review of Iclusig ®
(ponatinib) under the Article 20 referral procedure and has recommended
that Iclusig continue to be used in Europe in accordance with its
already approved indications.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.